August 22, 2019 – Boston, MA – Representatives from Abveris will attend the 17th Annual Discovery On Target Conference, September 16-19, 2019, in Boston, MA. Colby Souders, Chief Scientific Officer of Abveris, will serve as chairperson for the Antibody Engineering and Development Forum and present "Screening Tools for Early Prediction of Development and Clinical Success" at 3:40PM on Thursday, September 19. An abstract for the presentation is listed below.
As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage antibody characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating tools and methods into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. Comparisons across platforms, including traditional ELISA, flow cytometry, Octet and in vivo studies will be presented that provide enhanced prediction of downstream development and clinical success.
About Discovery On Target:
The 17th Annual Discovery on Target (DOT), the industry’s preeminent event on novel drug targets and technologies, will convene over 1,300 drug discovery professionals in Boston, MA, on September 16-19, 2019. This event highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.